

IMPACT FACTOR 4.5





an Open Access Journal by MDPI

Lung Cancer in Non-smokers

Guest Editors:

Dr. Andrew J. Kaufman

Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Prof. Dr. Raja M. Flores

Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Deadline for manuscript submissions:

15 November 2024

Message from the Guest Editors

In order to better understand this complex disease, we are pleased to invite you to contribute comprehensive and upto-date review articles that provide the most authoritative compendium of knowledge on LCINS to date. The aim of this Special Issue is to summarize the highest quality research to date, identify ongoing knowledge gaps and propose LCINS-related clinical and research initiatives. This Special Issue aims to focus on the following ten LCINS areas of critical importance:

- 1. Clinical epidemiology and risk factors;
- 2. Genetics, biology, and molecular carcinogenesis;
- 3. Pathologic characteristics and subtypes;
- 4. Screening for lung cancer in never smokers, focused on efficacy, outcomes, overdiagnosis and overtreatment;
- 5. Radiologic characteristics and natural history;
- 6. Targeted therapy, systemic therapy, immunotherapy, and novel therapeutics, and clinical outcomes;
- 7. Statistics, databases, and data analysis for LCINS;
- 8. Biomarkers for diagnosis, prognosis, and monitoring;
- 9. Surgical outcomes for LCINS;
- 10. Healthcare disparities in LCINS.

Any additional research ideas or concepts are welcome. We look forward to receiving your contributions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us